ClinicalTrials.gg
RecruitingNCT04868305TUFHIPRCTUpdated Apr 30, 2026

Intramedullary Nail Versus Hip Arthroplasty in Unstable Trochanteric Hip Fractures

An interventional study of Intramedullary nail and Hip arthroplasty in Hip Injuries and Disorders and Hip Fractures, sponsored by Helse Stavanger HF. Recruiting at 1 site in Norway. Open to participants aged 65 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Primary conditionHip FracturesRegistry: Hip InjuriesReclassifiedWhy we changed it
Registry
Hip Injuries — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hip Fractures
Why
  1. The study's listed conditions name Hip Fractures, a narrower term within Hip Injuries.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Helse Stavanger HF · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
65 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Hip Fractures with a site in Norway — 4 open to participants now, 6 under way, none of them phase 3. Hip Fractures · Norway.

Planned enrollment
14th of 25
170 · median 200
Started
2021
with 2 others
No phase
20 of 30
4 open now
Registered
25th of 30
by date
Lead sponsor
1 of 30
Helse Stavanger HF

Among the 30 studies in Hip Fractures with a site in Norway, this one is the 14th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2021, is one of 20 with no phase, and was the 25th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

4 of the 30 studies in Hip Fractures with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hip Fractures with a site in Norway, or all of them as a file.
02

Study summary

A hip fracture is a large burden to the patient with increased mortality, pain and increased need for daily assistance. Trochanteric fractures of the femur (FTF) represents about 35% of the hip fractures. Today FTFs are mainly treated with internal fixation using sliding hips screws (SHS) or intramedullary nail (IMN), whilst hip arthroplasty (THA/HA) is rarely used. Despite advances in the design of the internal fixation implants there is a high failure rate, in particular in cases of FTFs classified as unstable fractures. Since the introduction of hip arthroplasty in femoral neck fractures there has been a reduction in complication rates, early mobilization and shorter hospital stays.

The primary objective of this project is to investigate if treatment with hip arthroplasty in unstable FTFs will increase the postoperative mobility, give a better general health outcome for the patient, better quality of life and reduce re-operation rate for the patients compared to those operated with the traditional IMN.

Read the detailed description

Proximal femoral fractures also termed "hip" fractures are one of the most common fractures among adults over 50 years of age. With increase in life expectancy, the incidence of these fractures is also increasing. By 2040, the number of these fractures are expected to double in Norway. Trochanteric fractures of the femur (Fractura Trochanterica Femoris, FTF) represents about 35% of the hip fractures in Norway . There are many classification systems for FTFs, but The Orthopaedic Trauma Association (OTA) have adopted the system developed by the Arbeitsgemeinschaft Osteosynthese (AO ) group, and is the most commonly used in addition to the Evans Jensens classification.

The mean age of hip fracture patients is 82 years for women and 78 for men. The comorbidity in this patient group is high with large amount of dementia, sarcopenia and osteoporosis. The one-year mortality rate after a hip fractures is 20-35%. According to the Norwegian Hip Fracture Register 15 % of the hip fractures are unstable trochanteric fractures (AO 31A2.2-A3). The prognosis is poor, in particular for unstable (multi fragmented) fractures, with reported complications up to 35-51 %.

Substantial research has established better understanding and best practice guidelines to treat the femoral neck fractures, mostly with hip arthroplasty, however no superior method is established for the unstable trochanteric fractures. 'Getting It Right First Time' is important for these fragile patients, thus post-operative complications are associated with a large increase in the mortality.

Today, most of the FTFs are reduced and fixated with a sliding hip screw (SHS), although the use of intramedullary nails (IMN) is increasing. RCTs have shown better survival of IMN compared to SHS for the more distal FTFs and subtrochanteric fracture. Unstable FTFs (AO 31A2 - A3, EVJ III-V) have high reoperation rates (21-35%) when operated either with SHS or IMN. Unacceptable shortening, external rotation deformity of the limb and long time to recover/mobilization have been the problems with osteosynthesis.

The question is if hip arthroplasty can give a superior treatment outcome for patients suffering from unstable subtypes of trochanteric hip fractures compared to the traditional treatment with IMN. A randomized clinical trial is to be conducted comparing these two treatment methodologies.

Stavanger University Hospital (SUH) receives over 150 FTFs per year. About 1/3 of the FTFs are of unstable fracture morphology. The planned study is a randomized clinical trial. The randomization module will be provided by Klinisk forskningsenhet Midt-Norge (KlinForsk). Patients fulfilling the inclusion criteria will be randomized to one of two treatment groups, IMN versus hip arthroplasty.

Included patients will be treated in accordance to a local operation protocol:

Intramedullary nails will be operated by a resident orthopedic surgeon with at least 2 years' experience in fracture surgery or a consultant orthopedic surgeon (there must always be a consultant orthopedic surgeon present in the surgical team). A long IMN must always be utilized. Anatomical reposition or positive anterior and medial cortical support should be strived to be achieved. If a large antero- or posteromedial fragment is present one should consider an additional cerclage to fix the fragment.

Arthroplasty will be operated by a resident orthopedic surgeon with at least 2 years' experience with hip arthroplasty surgery or by a consultant orthopedic surgeon subspecialized in arthroplasty surgery, with competency within revision or difficult primary hip arthroplasty surgery (there must always be a consultant orthopedic surgeon subspecialized in arthroplasty surgery present in the surgical team). Posterior surgical approach will be used. If a cup is to be utilized it must be a cemented dual-mobility cup.

The patients will have follow-up appointments at 2-, 6 and 12 months postoperative. Following data will be collected:

  • Patient reported outcome measures (HOOS and EQ5D)
  • Timed up and go test
  • Trendelenburg test
  • Clinical leg length discrepancy
  • Radiological assessment from hip x-rays (AP and lateral)
03

Conditions studied

  • Hip Injuries and Disorders
  • Hip Fractures

Browse trials for

Keywords

  • Trochanteric hip fracture
  • Unstable trochanteric hip fractures
04

In context

Hip Fractures Reclassified

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

This study's planned enrollment of 170 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

Helse Stavanger HF is the lead sponsor of 97 studies on the registry; 18 are open to participants now.

Compared within Hip Fractures, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hip Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 65 years
  • American Society of Anesthesiology Score (ASA) \< 4
  • Ambulant with or without aid (preinjury)
  • Radiological verified unstable trochanteric hip fracture (AO 31A2.2 - 3.3)
  • Written consent obtained by patient or his/her next of kin

Exclusion criteria

Exclusion Criteria:

  • Previous hip surgery on ipsilateral or contralateral side
  • Non-ambulant preinjury
  • Patient not living in the area of hospital care
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    Intramedullary nail

    Intramedullary nail with proximal lagscrew and distal locking screw(s)

    Procedure: Intramedullary nail

  • Active comparator
    Hip arthroplasty

    Hemiarthroplasty (HA) or Total hip arthroplasty (THA). A cemented dual-mobility cup will be utilized in THA. Addition of cerclage/trochanter claw plate to fixate trochanter major will be used when suitable.

    Procedure: Hip arthroplasty

Interventions

  • ProcedureIntramedullary nail

    Intertan nail (Smith \& Nephew)\* or Gamma 3 nail (Stryker)\* \* All of the above-mentioned products are subjects to change into an equivalent product

  • ProcedureHip arthroplasty

    Total hip arthroplasty: * Cemented: Lubinus (Link)\*, Exeter (Stryker)\* * Uncemented: Restoration Modular (Stryker)\* * Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)\* Hemiarthroplasty: * Cemented: Lubinus (Link)\*, Exeter (Stryker)\* * Uncemented: Restoration Modular (Stryker)\* * All of the above-mentioned products are subjects to change into an equivalent product

07

What researchers measure

Primary outcomes

  1. Patient Reported Outcome Measure (PROM)

    Hip disability and Osteoarthritis Outcome Score (HOOS). "HOOS is developed as an instrument to assess the patients' opinion about their hip and associated problems. HOOS consists of 5 subscales; Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and hip related Quality of life (QOL). The last week is taken into consideration when answering the questions. Standardized answer options are given (5 Likert boxes) and each question gets a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. The result can be plotted as an outcome profile. * Above information about HOOS is copied from the authors of www.KOOS.nu * Change in HOOS score will be observed from 2-, 6- and 12 months.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  2. Patient Reported Outcome Measure (PROM)

    EuroQol EQ-5D. "The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement." Change in EQ-5D score will be observed from 2-, 6- and 12 months.

    Time frame: Collected from 2 to 12 months from primary surgery

Secondary outcomes

  1. Mortality

    Mortality rates will be analyzed

    Time frame: 2, 6 and 12 months from primary surgery

  2. Complications related to prosthesis

    Specific complications related to the randomly assign intervention; * Peri prosthesis fracture * Prosthesis dislocation * Prosthesis loosening * Dislocation of trochanter major * Surgical wound infection (superficial) * Deep surgical wound infection

    Time frame: Collected from 2 to 12 months from primary surgery

  3. Complications related to osteosynthesis

    Specific complications related to the randomly assign intervention; * Peri implant fracture (intraoperative or postoperative) * Implant cut-out * Non-union of fracture * Dislocation of trochanter major * Surgical wound infection (superficial) * Deep surgical wound infection

    Time frame: Collected from 2 to 12 months from primary surgery

  4. Somatic postoperative complications

    * Deep vein thrombosis or other thromboembolic event * Pressure sores * Neurological complications * Other

    Time frame: Collected from 2 to 12 months from primary surgery

  5. Reoperation rate

    Reoperation rate (and causes) within each intervention arm

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  6. Radiological assessment of horizontal center of rotation (prosthesis)

    Horizontal center of rotation (millimeter) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  7. Radiological assessment of vertical center of rotation (prosthesis)

    Vertical center of rotation (millimeter) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  8. Radiological assessment of acetabular inclination (prosthesis)

    Acetabular inclination (degrees) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  9. Radiological assessment of acetabular anteversion (prosthesis)

    Acetabular anteversion (degrees) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  10. Radiological assessment of femoral stem positioning (prosthesis)

    Femoral stem positioning (valgus, neutral, varus) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  11. Radiological assessment of leg length discrepancy (intramedullary nail)

    Leg length discrepancy (millimeter) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  12. Radiological assessment of femoral neck length (intramedullary nail)

    Femoral neck length (millimeter) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  13. Radiological assessment of hip offset (intramedullary nail)

    Hip offset (millimeter) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  14. Radiological assessment of tip-to-apex (intramedullary nail)

    Tip-to-Apex (millimeter) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  15. Radiological assessment of medial cortical support (intramedullary nail)

    Medial cortical support (negativ, neutral or positive) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  16. Radiological assessment of anterior cortical support (intramedullary nail)

    Anterior cortical support (negativ, neutral or positive) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  17. Radiological assessment of trochanter major dislocation (intramedullary nail)

    Trochanter major dislocation (millimeter) Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  18. Timed Up and Go test (TUG test)

    Timed Up and Go test is used to asses mobility at follow-up 2-, 6- and 12 months postoperative. Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  19. Trendelenburg test

    Trendelenburg test is used to assess hip abductor function at follow-up 2-, 6- and 12 months postoperative.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

  20. Clinical leg length discrepancy

    Clinical assessment of leg length discrepancy using 5 mm plates. Observation for eventual changes in above mentioned variable will be recorded throughout three follow-up appointments.

    Time frame: Collected at 2, 6 and 12 months from primary surgery

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Mar 2027, 65 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 65 months is above that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 30, 2021
StartActual
Oct 12, 2021
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04868305
Lead sponsor
Helse Stavanger HF
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
Oct 12, 2021
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

Thomas Abel Woldeyesus, MD
Contact
thomas.abel.woldeyesus@sus.no
+4751513488
Ane Djuv, MD., PhD
Contact
ane.djuv@sus.no
+4751518284
Ane Djuv, MD., PhD
principal investigator · Helse Stavanger HF
Jan-Erik Gjertsen, MD., PhD
study chair · Haukeland University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion